Therapeutic Management of Preterm Newborns with Patent Ductus Arteriosus in Epiclatino Units in the Period 2015-2020.

Introduction: In the new-born, persistent patent ductus arteriosus is associated with significant morbidity and mortality. Normally at birth, ductus arteriosus contracts causing intraluminal ischemic hypoxia that ultimately leads to closure and remodelling of the ductus. Currently, the medical management of PAD is based on the use of non-selective inhibitors of the cyclooxygenase enzyme that participates in the synthesis of prostaglandins, especially indomethacin, acetaminophen, and ibuprofen, which promote closure of the communication by up to 70% -93%. Materials and methods: Observational, retrospective, and analytical study in which records from the EpicLatino database were used. Results: 1243 patients were obtained, 52% of patients received some type of treatment and, 171 preterm patients received treatment with acetaminophen, with an increase in the trend in its use from the year 2015 to 2020. Conclusions: More treatment was used as lower the gestational age was. The use of indomethacin and ibuprofen has decreased from 2015 to 2020 due to the adverse effects they cause compared to acetaminophen.